Third-Line Therapy in Metastatic Colorectal Cancer

被引：2
|
作者：
van de Haar, Joris [1 ]
Valeri, Nicola [2 ]
Voest, Emile E. [1 ]
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Inst Canc Res, London, England
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 02期
关键词：
D O I：
10.1056/NEJMc2306486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：190 / 191
页数：2
相关论文
共 50 条
  • [31] Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer
    Ho, M. Y.
    Renouf, D. J.
    Cheung, W. Y.
    Lim, H. J.
    Speers, C. H.
    Zhou, C.
    Kennecke, H. F.
    [J]. CURRENT ONCOLOGY, 2016, 23 (05) : 329 - 333
  • [32] Retrospective review of mitomycin C use as third-line chemotherapy in metastatic colorectal cancer
    Chua, Wei
    Beale, Philip
    Leung, Melissa
    Clarke, Stephen
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2008, 4 (03) : 132 - 136
  • [33] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
  • [34] Irinotecan combined with Panitumumab or cetuximab as third-line treatment for metastatic colorectal cancer.
    Braghiroli, Maria Ignez
    Batistuzzo Vicentini, Maria Fernanda
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Bonadio, Renata Colombo
    Melro Braghiroli, Oddone Freitas
    Machado Mathias, Maria Cecilia
    Talans, Aley
    Zambrano Mendoza, Maria Elizabeth
    Martins, Juliana Goes
    Sabagga, Jorge
    Motta Venchiarutti Moniz, Camila Venchiarutti
    Hoff, Paulo Marcelo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15551 - E15551
  • [35] Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases
    Boudinar, F.
    Larbaoui, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [36] PHASE II STUDY OF OXALIPLATIN AS THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Sikder, S. K.
    Rahman, M.
    Saha, R. K.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 219 - 219
  • [37] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Metastatic colorectal cancer- third line therapy and beyond
    Foo, Tiffany
    Roy, Amitesh
    Karapetis, Christos
    Townsend, Amanda
    Price, Timothy
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (05) : 219 - 227
  • [39] THIRD-LINE FOLFIRI IN METASTATIC GASTRIC CANCER PATIENTS
    Caparello, C.
    Vasile, E.
    Lencioni, M.
    Fabrini, M. G.
    Lucchesi, M.
    Ginocchi, L.
    Caponi, S.
    Santi, S.
    Ricci, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 251 - 251
  • [40] Muscle quantity and quality in metastatic colorectal cancer patients during third-line therapy with regorafenib or TAS102
    Maddalena, C.
    Ponsiglione, A.
    Camera, L.
    Santarpia, L.
    Pasanisi, F.
    Bruzzese, D.
    D'Amato, M.
    Carlomagno, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S292 - S292
12345